Title: Targeting Sphingosine Kinase by ABC294640 against Diffuse Intrinsic Pontine Glioma (DIPG)

Running Title: ABC294640 and DIPG

Authors: Lu Dai¹#, Jungang Chen¹#, Zhen Lin²#, Zhaoxiong Wang², Shengyu Mu³, and Zhiqiang Qin¹*

Affiliations: Departments of Pathology¹, Pharmacology & Toxicology³, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA

²Department of Pathology, Tulane University Health Sciences Center, Tulane Cancer Center, 1700 Tulane Ave., New Orleans, LA 70112, USA

# These authors have equal contribution.

*Correspondence to: University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA. Phone: (501) 526-8619. E-mail: zqin@uams.edu (Dr. Zhiqiang Qin)
Abstract
As a highly aggressive pediatric brainstem tumor, Diffuse intrinsic pontine glioma (DIPG) accounts for 10% to 20% of childhood brain tumors. The survival rate for DIPG remains very low, with a median survival time as less than one year even under radiotherapy, the current standard treatment. Moreover, more than 250 clinical trials have failed when trying to improve the survival compared to radiotherapy. The sphingolipid metabolism and related signaling pathways have been found closely related to cancer cell survival, however, the sphingolipid metabolism targeted therapies have never been investigated in DIPG. In the current study, the anti-DIPG activity of ABC294640, the only first-in-class orally available Sphingosine kinase (SphK) inhibitor was explored. Treatment with ABC294640 significantly repressed DIPG cell growth by inducing intracellular pro-apoptotic ceramides production and cell apoptosis. We also profiled ABC294640-induced changes in gene expression within DIPG cells and identified many new genes tightly controlled by sphingolipid metabolism, such as IFITM1 and KAL1. These genes are required for DIPG cell survival and display clinical relevance in DIPG patients’ samples. Together, our findings in this study indicate that targeting sphingolipid metabolism may represent a promising strategy to improve DIPG treatment.

Keywords: sphingolipid; ceramide, brain tumor, DIPG, pediatric cancer
Introduction

Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor that accounts for about 10% to 20% of childhood brain tumors [1-3]. These tumors are mostly seen in children between 5 and 10 years old, but have been reported to occur at any age of childhood. The survival rate for DIPG remains very low, with a median survival time as less than one year even under radiotherapy, the current standard treatment. Moreover, more than 250 clinical trials have failed when trying to improve the survival compared to radiotherapy [4-6]. For example, some studies have reported chemotherapy has failed to show benefits beyond radiotherapy for improving DIPG patients’ survival [5]. Moreover, the sensitive location of these tumors and lack in surgical specimens (or even lack in the patient-derived cell lines) have hindered our understanding of the DIPG development, pathogenesis as well as discovery of effective targeted therapy. We and others recently have reported some new therapeutic targets and agents against DIPG, including natural products (e.g., Brefeldin A, Combretastatin A4); Emtansine conjugated to peptide nanofiber precursor (DM1-NFP); synthesized novel platinum(ii) complexes; combined AXL and HDAC inhibition [7-12]. However, most of these new treatments are still at preclinical stage, which require clinical trials to assess their efficacy and tolerability. Unfortunately, a very recent Phase 2 study reported that addition of valproic acid (VPA) and bevacizumab to radiation failed to improve the survival of DIPG patients [13].

The ceramidase in sphingolipid metabolism is responsible for hydrolytic conversion of ceramide to sphingosine, which is then phosphorylated by SphK1 or SphK2, two isoforms of sphingosine kinases to generate sphingosine-1-phosphate (S1P) [14]. In fact, the cellular balance of ceramide and S1P can determine the fate of tumor cells, with the accumulation of ceramides favoring cell apoptosis, while the accumulation of S1P favoring cell proliferation [14, 15]. Among sphingolipid metabolic, ceramide has been considered as a central lipid mediator with tumor suppression function, because it can tightly regulate many cellular signaling related to apoptosis, cell cycle and autophagy [14, 16]. Due to their pleiotropic roles, targeting bioactive sphingolipids has recently evolved as a promising therapeutic approach for improving cancer treatment [17]. As a key enzyme of sphingolipid metabolism, a highly selective small molecule inhibitor of SphK, 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (named as ABC294640), has been recently developed [18, 19], and shows significant anti-tumor effects on a variety of cancers [20-24]. Moreover, Britten et al have reported the promising results from a
Phase I clinical trial about ABC294640 in patients with advanced solid tumors [25]. They reported that ABC294640 at 500 mg bid was well tolerated by these cancer patients and achieved biologically relevant concentrations in their plasma [25].

Our group reported that targeting sphingolipid metabolism with either ABC294640 or exogenous ceramides resulted in \textit{in vitro} and \textit{in vivo} anticancer activities for virus-associated malignancies [20, 26-28], as well as non-small cell lung cancer (NSCLC) [29]. However, the functional role of sphingolipid metabolism and related cellular network in DIPG remains almost unknown. Even ABC294640 has displayed broad anti-tumor activities in a variety of cancers, we think that the underlying mechanisms especially sphingolipid related cellular contents are tumor type-dependent. It is also unclear whether the sphingolipid metabolism targeted therapies can be developed for improving DIPG treatment. In the current study, we investigated the response of DIPG cells to SphK inhibition by ABC294640, identified new cellular genes controlled by sphingolipid metabolism in DIPG cells and validated their functions in DIPG pathogenesis. Our results provide new insights into the mechanism and potential utility of targeting sphingolipid metabolism in a deadly form of pediatric cancer.

\textbf{Materials and Methods}

\textit{Cell culture and reagents}

The DIPG cell lines SF8628 and SF7761 that harbor the histone H3.3 Lys 27-to-methionine (K27M) mutation were purchased from Millipore-Sigma and cultured as recommended by the manufacturer. The cortical neuronal cell-line, HCN-2, was purchased from American Type Culture Collection (ATCC), and cultured as recommended by the manufacturer. All the experiments were carried out using cells harvested at low (<20) passages. ABC294640 was purchased from SelleckChem.

\textit{Cell proliferation and apoptosis assays}

Cell proliferation was determined by using the WST-1 assays (Roche) according to the manufacturer’s instructions. Briefly, after the period of treatment of cells, 10 μL/well of cell proliferation reagent, WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitro- phenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate), was added into 96-well microplate and incubated for 3 h at 37°C in 5% CO₂. The absorbance of samples was measured by using a microplate reader at 490 nm. Flow cytometry
was used to the quantitative analysis of apoptosis with the FITC-Annexin V/propidium iodide (PI) Apoptosis Detection Kit I (BD Pharmingen).

**Soft agar assays**

The anchorage-independent growth ability was determined using the soft agar assays as described previously [30]. Briefly, a base layer containing 0.5% agarose medium and 5% FCS was poured into the six-well plates. Then, 2,000 cells were mixed with 0.4% agarose in Dulbecco's Modified Eagle Medium (DMEM) containing 5% (v/v) FCS to form a single-cell suspension. The plates were then incubated for 4-5 weeks at 37 °C. Colonies were stained with 0.005% (w/v) crystal violet and photographed under a phase-contrast microscope.

**Immunoblotting**

Total cell lysates (20 μg) were resolved by 10% (w/v) SDS–PAGE, transferred to nitrocellulose membranes, and immunoblotted with antibodies for cleaved Caspase3, cleaved PARP, Bax, XIAP, SphK1, SphK2 (Cell Signaling), IFITM1, KAL1 (Abcam) and β-Actin or Tubulin (Sigma) for the loading controls. Immunoreactive bands were identified using an enhanced chemiluminescence reaction (Perkin-Elmer), and visualized by the autoradiography.

**Sphingolipid analyses**

Quantification of sphingolipid species was performed using a Thermo Finnigan TSQ 7000 triple-stage quadruple mass spectrometer (Thermo Fisher Scientific). Quantification was based on calibration curves generated by spiking an artificial matrix with known amounts of target standards and an equal amount of the internal standard. The ratio of sphingolipid normalized to total phospholipid phosphate level was shown as final results using the Bligh and Dyer lipid extract method as described previously [31].

**RNA-Sequencing and analysis**

RNA-Sequencing for each sample was performed in biological triplicate using the Genome Analyzer IIx (Illumina) at LSUHSC Translational Genomics Core (TGC) Facility. The completed RNA-Sequencing data has been submitted to NCBI Sequence Read Archive and available (SRA, accession # PRJNA565990). Raw sequencing reads were analyzed using the RSEM software (version 1.3.0; human GRCh38 genome sequence and annotation) for quantification of human gene expression as previously described.25 The EBSeq software was
utilized to analyze statistically differentially expressed genes using a false discovery rate (FDR) < 0.05. Differentially expressed genes between the ABC294640- and vehicle-treated cells were used as input for the Ingenuity Pathway Analysis (IPA)’s downstream effects analyses including the canonical pathway analysis and disease function analysis. The Z-score was calculated by the Z-score algorithm of the IPA, which can predict the direction of a biological function change. RNA-Sequencing data of DIPG tumor samples and paired normal brain tissues were obtained from the National Institutes of Health (NIH) Genotypes and Phenotypes (dbGaP) database under the accession number (SRA# SRP136329) after obtaining the NIH permission. Transcript quantification of human genes was conducted as previously described [32].

**RNA interference (RNAi) assays**

For RNAi assays, *IFITM1*, *KAL1*, *SphK1* or *SphK2* On-Target plus Smart pool siRNA (Dharmacon) or negative control siRNA were delivered at the concentration of 10 or 25 nM, using the DharmaFECT transfection reagent as recommended by the manufacturer.

**Statistical analysis**

The two-tailed Student's t-test was used to determine the significance for differences between the experimental and control groups.

**Results**

**ABC294640 displays effective anti-DIPG activity**

As mentioned above, currently there are limited patient-derived DIPG cell lines commercially available. Here we used two DIPG cell lines, SF8628 and SF7761, both of which are derived by surgical biopsies from H3.3K27M DIPG patients [33]. H3.3K27M, a somatic mutation of histone H3.3 resulting in a lysine 27 to methionine substitution occurs in 60% of DIPG [34]. In H3.3K27M DIPG patient samples, the levels of H3K27 dimethylation (H3K27me2) and trimethylation (H3K27me3) are reduced globally. These epigenetic changes are thought to be important factors driving DIPG oncogenesis [34, 35]. In a time-course “killing” assay, we found that ABC294640 treatment effectively reduced SF8628 cell growth in a dose-dependent manner when compared to the vehicle-treated controls (**Figure. 1A**). We also observed similarly inhibitory effects of ABC294640 on SF7761 cell line (**Figure. S1**). In contrast, ABC294640 showed much
less inhibitory effects on the growth of normal brain/neuronal cell-line, HCN-2, only 80 μM concentration showing limited inhibition (Figure. S2). Even though both DIPG cell lines carrying H3.3K27M, they display distinct morphology in cultures, especially SF7761 having much less adhesive capability, easily clustering (not good for WST-1 assays measurement), and difficult being cultured (Figure. S3), so we decided to only use SF8628 for subsequent experiments. We next sought to determine the mechanisms for anti-DIPG activity of ABC294640. Using flow cytometry, we found that ABC294640 treatment induced apoptosis of DIPG cells in a dose-dependent fashion, including the increased subpopulation of both early (Annexin V+/PI-) and late (Annexin V+/PI+) apoptotic cells (Figure. 1B-C). We also observed the increased cleavage of caspases-3 and PARP, and the expression of pro-apoptotic protein, Bax, from ABC294640-treated DIPG cells (Figure. 1D). In contrast, we observed a decreased expression of X-linked inhibitor of apoptosis protein (XIAP), which is a physiologic substrate of Akt, and its function is stabilized to inhibit programmed cell death and having a direct effect on caspases [36]. These results are consistent with the notion that ABC294640 exerts an anti-proliferative effect on DIPG cells by inducing programmed cell death.

**ABC294640 induces intracellular ceramides production from DIPG cells by lipidomics analysis**

Next, we sought to determine if these effects were related to changes in sphingolipid metabolism. Mass spectrometric (MS)-based lipidomics analysis were used to quantify and compare intracellular levels of bioactive ceramide species in the SF8628 cell line treated with or without ABC294640. We found that ABC294640 increased total levels of intracellular ceramides (~8 folds) in DIPG cells when compared to the vehicle group. The lipidomics analysis showed that most of individual ceramide species including those from C14-Cer to C26-Cer were upregulated in ABC294640-treated DIPG cells, although the extent of the increase varies among the ceramide species (Figure. 1E-F). The composition and proportion of ceramide species within SF8628 cells with or without ABC294640 treatment were calculated (Figure. S4). The predominant ceramide signature within DIPG cells included C16-, C22- and C24:1-Cer species. Interestingly, we found that ABC294640 treatment did not significantly alter the proportion of ceramide species in DIPG cells, which is different from what we have observed in virus-associated tumors and lung cancers [26, 28, 29].
Transcriptomic analysis of gene profiling altered within ABC294640-treated DIPG cells

To determine the global metabolic and cellular changes induced by ABC294640, we compared the global gene profile altered between vehicle- and ABC294640-treated tumor cells by using RNA-Seq (Illumina) analysis. We first found 485 genes significantly upregulated and 782 genes significantly downregulated (≥ 2 folds and FDR < 0.05) in ABC294640-treated SF8628 cell line, respectively (Figure. 2A). The top 20 significantly upregulated and downregulated candidates were listed in Table 1. Interestingly, most of these candidates, their functions have never been reported in DIPG cells. Ingenuity pathway analysis (IPA) analysis of altered gene profiling indicated that many canonical pathways and disease_function categories within DIPG cells were affected by ABC294640 treatment (Figure. 2B-C). For example, several canonical pathways related to cancer cell survival, such as retinoic acid mediated apoptosis signaling, cyclins and cell cycle regulation, and calcium signaling were impacted by treatment with ABC294640. Since ABC294640 is a selective SphK inhibitor, it is not surprising to see several fatty acid/lipid synthesis categories negatively regulated by ABC294640.

Sphingolipid metabolism regulation of IFITM1 and KAL1 which are required for DIPG cell survival

To functionally validate those significantly altered genes within ABC294640-treated DIPG cells discovered by RNA-Seq, we selected two candidates, IFITM1 and KAL1, from the list. Interferon-induced transmembrane protein 1 (IFITM1) is originally identified as part of membrane complexes transducing homotypic adhesion signals in lymphocytes [37, 38]. The expression of IFITM1 is induced by IFN-α and/or IFN-γ (to a lesser extent), and has been reported in several types of cancer cells [39, 40]. Anosmin-1, encoded by the KAL1 gene, is an important extracellular matrix (ECM) component that plays essential roles in the establishment of olfactory and gonadotrophin-releasing hormone (GNRH) neurons during early brain development. Loss-of-function mutations of KAL1 results in Kallmann syndrome with delayed puberty and anosmia [41]. However, their functions in DIPG cells remain unclear.

We observed the downregulation of both IFITM1 and KAL1 in DIPG cells treated with ABC294640 (Table 1). We next found that silencing of either IFITM1 or KAL1 by RNAi effectively repressed DIPG cell growth, inducing tumor cell apoptosis in a manner similar to treatment with ABC294640 (Figure. 3A-C). RNAi against either IFITM1 or KAL1 also inhibited
anchorage-independent growth of DIPG cells (Figure. 3D-E), again consistent with the results obtained in experiments with the SphK inhibitor.

Currently, a DIPG clinical database is not publically available. Recently, we have obtained the permission to access RNA-Sequencing data of DIPG tumor samples and paired normal brain tissues from the NIH Genotypes and Phenotypes (dbGaP) database. Here we found that both IFITM1 and KAL1 expression were higher in DIPG tumor samples than in their paired normal brain tissues, although only KAL1 proved to be statistically significant probably due to the small number of collection (Figure. 3F). Together, these data support a role for IFITM1 and KAL1 in promoting DIPG survival or growth.

To further understand the connection of IFITM1 and KAL1 with sphingolipid metabolism in DIPG cells, we silenced SphK1 and SphK2 in SF8628, two of major enzymes in sphingolipid metabolism using RNAi, respectively. We found that knockdown of either SphK1 or SphK2 effectively reduced IFITM1 and KAL1 expression (Figure. 3G), indicating sphingolipid metabolism indeed regulates these cellular genes expression and functions to determine tumor cell survival.

Discussion

As a rare but highly aggressive pediatric cancer, DIPG is currently lacks an effective treatment, making prognosis very poor. Our efforts seek to identify new therapeutic targets and develop promising strategies for maximally prolonging the survival of patients. In the current study, we used one of few commercially available DIPG patient-derived cell lines (SF8628) to determine if targeting sphingolipid metabolism is a useful strategy for improving patient outcomes. We found that treatment with ABC294640, the only first-in-class orally available inhibitor of SphK, selectively repressed DIPG cell growth through inducing intracellular pro-apoptotic ceramides production and tumor cell apoptosis. In general, there are three major ceramide generation pathways: the sphingomyelinase pathway (sphingomyelin→ceramide); the de novo pathway (3-keto-dihydrosphingosine→dihydro sphingosine→dihydroceramide→ceramide); and the Salvage pathway (S1P→sphingosine→ceramide) [16, 42]. MS-based lipidomics analyses will be used to further determine which pathways mediate intracellular ceramides production from ABC294640-treated DIPG cells. Ceramide synthases (CerSs) are the enzymes responsible for ceramide generation in the de novo and Salvage pathways. Currently, six different CerSs have been
identified in mammary cells, CerS1-6 [43], and different isoforms of CerS generate an array of ceramide species with distinct length of fatty acid chain [44]. Our previous study showed that ABC294640 treatment increased the gene transcription and protein expression for CerS2, CerS4 and CerS6 from some virus-associated lymphomas [26]. However, the signature of ceramide species and regulation of ceramide production are potentially differentiated in different types of cancer cells. For example, we found that ABC294640 treatment did not alter the proportion of ceramide species in DIPG cells, in contrast to the significant changes we observed previously in virus-associated tumors and lung cancers [26, 28, 29]. In addition, we previously reported that ABC294640 treatment induced dihydro(dh)-ceramide production in virus-associated tumors and lung cancers, which also contributed to “killing” of tumor cells [20, 28, 29]. In contrast, we found low or undetectable levels of dh-ceramide species in DIPG cells even after exposure to ABC294640 (data not shown), implying that dh-ceramides are not involved in ABC294640-mediated DIPG cell death.

Although the functional role of sphingolipid metabolism (especially ceramide production) and targeted therapy have not been reported in DIPG, there are some related reports in other brain tumors. One recent study reported that the overexpression of CerS1 increased C18-Cer level and led to lethal autophagy in human glioma cells [45]. Another recent study revealed that co-delivery of tumor-derived exosomes with α-galactosylceramide (α-GalCer) on a dendritic cell (DC)-based vaccine showed excited effects on glioblastoma immunotherapy, inducing strong activation of tumor-specific cytotoxic T lymphocytes, synergistically breaking immune tolerance and improving the immunosuppressive environment in vivo [46]. In one review article, Sordillo et al postulated that some chemotherapeutic agents or radiotherapy may induce short-term responses in glioblastoma patients by increasing ceramide levels, however, the SphK may cause the increased ceramide to be metabolized to S1P, therefore restoring the abnormally high S1P to ceramide balance and representing part of the reason for the nearly 100% recurrence rate of glioblastoma [47]. Thus, the use of maintenance therapy with a SphK inhibitor in patients with glioblastoma who have tumor reduction or stable disease after therapy should be investigated and considered.

In addition to the regulation of intracellular ceramides production, sphingolipid metabolism actually regulates many other cellular factors related to cell survival or death. Our recent transcriptomic analyses revealed that a subset of tumor suppressor genes (~25 genes) were significantly upregulated in virus-associated lymphomas by exogenous dhC16-Cer [27], which
may control tumor cell growth. In this study, we have identified new genes within DIPG affected by ABC294640. Two of these genes, IFITM1 and KAL1, were selected and found to have a strong impact on DIPG cell survival with clinical relevance. Interestingly, Balbous et al reported IFITM1 as one of mesenchymal glioma stem cell makers responsible for cell invasion and gliomasphere initiation, which also revealed strong correlation with overall survival of glioblastoma patients [48]. Several studies reported overexpression of IFITM1 in some types of tumors, such as colorectal, gastrointestinal and breast cancers [49, 50]. Furthermore, these studies demonstrated a positive correlation between IFITM1 overexpression and tumor progression, too. For another gene, KAL1, Choy et al found that its mRNA level was significantly upregulated in high-grade primary brain tumors when compared to the normal brain and/or low-grade tumors [51]. They also found that KAL1 enhanced glioblastoma cells proliferation and motility in vitro, through forming a complex with integrin β1 induced downstream signaling, and modulating cell adhesion [51]. Interestingly, we found that both SphK1 and SphK2 could regulate IFITM1 and KAL1 expression, although ABC294640 has much less impact on SphK1 when compared to SphK2. Thus our data demonstrate that sphingolipid metabolism indeed regulates the expression of other cellular factors related to DIPG survival such as IFITM1 and KAL1, while the regulatory mechanisms still require further investigation.

In conclusion, our data for the first time demonstrate sphingolipid metabolism controls DIPG cell survival, which may represent a promising target against this rare but deadly pediatric brain tumor. Our findings also provide new evidence that sphingolipid metabolism regulates additional cellular factors to affect DIPG cell survival and growth. Although its promising in DIPG treatment, there are still many challenging for developing sphingolipid metabolism targeted therapy including ABC294640. One of remained questions is the permeability and uptake of ABC294640 to blood-brain barrier (BBB) and blood-tumor barrier (BTB), which have never been tested before. Also, the in vivo efficacy of ABC294640 or other sphingolipid-related agents need to be assessed by using DIPG intracranial animal models in future studies.

Acknowledgements

We thank Dr. Jovanny Zabaleta at LSUHSC to help the RNA-sequencing and Dr. Robert Eoff at UAMS to help discussion and edition during the manuscript preparation. This work is supported by the Arkansas Bioscience Institute, the major research component of the Arkansas
Tobacco Settlement Proceeds Act of 2000 (to Z.Q.). S.M. is supported by NIH 1R01 HL146713. Z.L. is supported by a NIH COBRE grant (P20 GM121288), a Tulane school of medicine faculty research pilot grant, and a Carol Lavin Bernick faculty grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests**

All the authors declare no competing interests.

**References**


Figure legends:

Figure 1. ABC294640 treatment effectively reduces DIPG proliferation through inducing tumor cell apoptosis and intracellular ceramides production. (A) DIPG cell line SF8628 were treated with the indicated concentrations of ABC294640 or vehicle for 24-96 h. The cell proliferation status was then examined using the WST-1 cell proliferation assays (Roche). (B-C) SF8628 were treated with the indicated concentrations of ABC294640 or vehicle for 24 h. Cell viability and apoptosis were then measured by Annexin V-PI staining and flow cytometry analysis. Error bars represent S.D. for 3 independent experiments. (D) Protein expression was detected using immunoblots. (E-F) SF8628 were treated with 40 µM of ABC294640 or vehicle for 24 h. Ceramide species and total levels were then quantified using lipidomics analyses as described in the Methods. Error bars represent S.D. for 2 independent experiments. ** = p< 0.01.

Figure 2. Ingenuity pathway analysis (IPA) of global gene profile altered by ABC294640 from DIPG cells. (A) The RNA-Sequencing (Illumina) was used to investigate the transcriptome change between ABC294640 and vehicle treated DIPG SF8628 cells. The significantly changed genes (expression change ≥ 2-fold and p<0.05) were shown in the Volcano plot panels. (B-C) The top 10 activated (red) and 10 inhibited (blue) canonical pathways (or Disease_functions) discovered in the ABC294640-treated cells by the IPA. The pathways (B)/functions (C) were ranked by the Z-score. The Z-score is a value calculated by the Z-score algorithm of the IPA. The Z-score is utilized to predict the direction of change for a biological function: if it is increased, the Z-score is > 0; if it is decreased, the Z-score is < 0.

Figure 3. Sphingolipid metabolism regulation of IFITM1 and KAL1 expression is essential for DIPG cell survival and growth. (A-C) SF8628 were transfected with IFITM1-siRNA, KAL1-siRNA or non-target control siRNA (n-siRNA) for 48-96 h, then the protein expression, cell proliferation and apoptosis were measured as described above. (D-E) The anchorage-independent growth ability was determined using the soft agar assays. Error bars represent S.D. for 3 independent experiments. ** = p< 0.01. (F) The expression of IFITM1 and KAL1 in 10 DIPG and paired normal brain tissues. RPKM (Reads Per Kilobase of transcript per Million mapped reads) values were calculated using reads across the gene exons. Data were represented as the mean (+/-) SEM. (G) SF8628 were transfected with SphK1-siRNA, SphK2-siRNA or non-target control siRNA (n-siRNA) for 72 h, then the protein expression was measured by immunoblots.
Table 1. The top 20 candidate genes upregulated or downregulated in DIPG cells treated by ABC294640.

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Description</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>TM4SF19-TCTEX1D2</td>
<td>TM4SF19-TCTEX1D2</td>
<td>203.2956944</td>
</tr>
<tr>
<td>SERPINB2</td>
<td>Serpin family B member 2</td>
<td>198.8279343</td>
</tr>
<tr>
<td>CXCL8</td>
<td>C-X-C motif chemokine ligand 8</td>
<td>175.8729164</td>
</tr>
<tr>
<td>AP003419.11</td>
<td>AP003419.11/novel protein</td>
<td>166.9185386</td>
</tr>
<tr>
<td>KRT34</td>
<td>Keratin 34</td>
<td>163.7514827</td>
</tr>
<tr>
<td>RP11-466H18.1</td>
<td>Ribosomal protein L36a pseudogene</td>
<td>153.5685184</td>
</tr>
<tr>
<td>ANKRD22</td>
<td>Ankyrin repeat domain 22</td>
<td>139.5586948</td>
</tr>
<tr>
<td>CH507-9B2.4</td>
<td>CH507-9B2.4/novel protein</td>
<td>92.99857464</td>
</tr>
<tr>
<td>SPINK1</td>
<td>Serine peptidase inhibitor, Kazal type 1</td>
<td>88.91478078</td>
</tr>
<tr>
<td>SLC7A11-AS1</td>
<td>SLC7A11 antisense RNA 1</td>
<td>83.299466</td>
</tr>
<tr>
<td>ANGPTL4</td>
<td>Angiopoietin like 4</td>
<td>79.47843571</td>
</tr>
<tr>
<td>CORO7-PAM16</td>
<td>CORO7-PAM16</td>
<td>75.18388531</td>
</tr>
<tr>
<td>CTD-2066L21.3</td>
<td>CTD-2066L21.3/lincRNA</td>
<td>71.37901957</td>
</tr>
<tr>
<td>AC068533.7</td>
<td>AC068533.7/novel protein</td>
<td>70.82918348</td>
</tr>
<tr>
<td>RP11-1151B14.4</td>
<td>Novel transcript, antisense to ALPK2</td>
<td>62.40569457</td>
</tr>
<tr>
<td>CXorf67</td>
<td>Chromosome X open reading frame 67</td>
<td>58.1829534</td>
</tr>
<tr>
<td>IL36B</td>
<td>Interleukin 36, beta</td>
<td>53.78426467</td>
</tr>
<tr>
<td>TNFSF12-TNFSF13</td>
<td>TNFSF12-TNFSF13</td>
<td>51.2770121</td>
</tr>
<tr>
<td>GPR78</td>
<td>G protein-coupled receptor 78</td>
<td>51.25501866</td>
</tr>
<tr>
<td>RP11-613M10.8</td>
<td>RP11-613M10.8/novel protein</td>
<td>50.4192678</td>
</tr>
<tr>
<td>COL3A1</td>
<td>Collagen type III alpha 1 chain</td>
<td>0.003891426</td>
</tr>
<tr>
<td>IFITM1</td>
<td>Interferon induced transmembrane protein 1</td>
<td>0.006783706</td>
</tr>
<tr>
<td>LGALS2</td>
<td>Galectin 2</td>
<td>0.009437712</td>
</tr>
<tr>
<td>HEYL</td>
<td>Hes related family bHLH transcription factor with YRPW motif-like</td>
<td>0.0097645</td>
</tr>
<tr>
<td>RP11-588K22.2</td>
<td>Novel transcript, overlapping GUCY1A3</td>
<td>0.01022648</td>
</tr>
<tr>
<td>AC093850.2</td>
<td>AC093850.2/novel transcript</td>
<td>0.011349859</td>
</tr>
<tr>
<td>DUSP27</td>
<td>Dual specificity phosphatase 27</td>
<td>0.012750501</td>
</tr>
<tr>
<td>TLL1</td>
<td>Tolloid like 1</td>
<td>0.012939696</td>
</tr>
<tr>
<td>RP11-680F20.6</td>
<td>V-set and immunoglobulin domain-containing protein 10-like</td>
<td>0.013194198</td>
</tr>
<tr>
<td>C1QTNF3-AMACR</td>
<td>C1QTNF3-AMACR</td>
<td>0.01373263</td>
</tr>
<tr>
<td>APOC1</td>
<td>Apolipoprotein C1</td>
<td>0.014431779</td>
</tr>
<tr>
<td>CDH23</td>
<td>Cadherin related 23</td>
<td>0.015076107</td>
</tr>
<tr>
<td>TEX41</td>
<td>Testis expressed 41</td>
<td>0.015646885</td>
</tr>
<tr>
<td>KAL1</td>
<td>Anosmin 1</td>
<td>0.015662941</td>
</tr>
<tr>
<td>COL5A3</td>
<td>Collagen type V alpha 3 chain</td>
<td>0.016356182</td>
</tr>
<tr>
<td>Gene</td>
<td>Description</td>
<td>Value</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>DLX3</td>
<td>Distal-less homeobox 3</td>
<td>0.017533291</td>
</tr>
<tr>
<td>RP11-598P20.5</td>
<td>RP11-598P20.5/novel protein</td>
<td>0.017621652</td>
</tr>
<tr>
<td>ZMYND15</td>
<td>Zinc finger MYND-type Containing 15</td>
<td>0.017651757</td>
</tr>
<tr>
<td>MUC7</td>
<td>Mucin 7, secreted</td>
<td>0.017651757</td>
</tr>
</tbody>
</table>